{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:06:38Z","timestamp":1788872798905,"version":"build-2803163510"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint blockade has changed the therapeutic landscape of cervical cancer, but clinical benefit remains heterogeneous and difficult to predict with single biomarkers. Cervical cancer is a particularly suitable setting for immune-cell profiling because HPV-driven antigenicity, chemoradiotherapy-induced tissue remodeling, anti-angiogenic combinations, and repeated exposure to PD-1\/PD-L1 inhibitors all shape the blood-tumor immune axis. This Mini Review discusses how circulating immune cells and tumor-infiltrating immune cells can be jointly interrogated by multi-omics technologies to identify biomarkers of response and resistance. We focus on single-cell RNA sequencing, T-cell receptor\/B-cell receptor (TCR\/BCR) profiling, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), flow cytometry, spatial transcriptomics, high-plex spatial proteomics, bulk transcriptomics, cytokine profiling, and circulating tumor DNA (ctDNA)-informed longitudinal designs. Recent cervical cancer atlases suggest that response is unlikely to be explained by total immune infiltration alone, but instead reflects the spatial organization and functional states of cytotoxic T cells, NK cells, antigen-presenting cells, tertiary lymphoid structure (TLS) programs, regulatory T cells, myeloid cells, and cancer-associated fibroblasts (CAFs). We propose a blood-to-tumor framework in which dynamic peripheral phenotypes may monitor systemic immune competence, while tissue multi-omics may identify local immune exclusion, terminal exhaustion, and myeloid suppression. Prospective paired sampling and interpretable, externally validated AI-assisted computational integration are needed before these biomarkers can guide treatment selection.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1925452","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:58Z","timestamp":1788869278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Wangshu","family":"Li","sequence":"first","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yu","sequence":"additional","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Ningxia Medical University General Hospital","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz ur Rehman","family":"Aziz","sequence":"additional","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children\u2019s Medical Group","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Ningxia Medical University General Hospital","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.669587","article-title":"Response to immune checkpoint inhibitor treatment in advanced cervical cancer and biomarker study","volume":"8","author":"Shieh","year":"2021","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e105","article-title":"Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer","volume":"35","author":"Baek","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152352","article-title":"Advancing personalized medicine in LMICs: predictive indicators for cervical cancer immunotherapy response","volume":"52","author":"Eksteen","year":"2025","journal-title":"Semin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1620501","article-title":"Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s42003-022-04142-w","article-title":"Single-cell transcriptomics reveals cellular heterogeneity and molecular stratification of cervical cancer","volume":"5","author":"Li","year":"2022","journal-title":"Commun Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add8977","article-title":"Single-cell dissection of cellular and molecular features underlying human cervical squamous cell carcinoma initiation and progression","volume":"9","author":"Liu","year":"2023","journal-title":"Sci Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110757","article-title":"Single-cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment","volume":"42","author":"Cao","year":"2023","journal-title":"EMBO J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203040","article-title":"Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma","volume":"9","author":"Ou","year":"2022","journal-title":"Adv Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01570-0","article-title":"Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance","volume":"55","author":"Fan","year":"2023","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28857","article-title":"Diverse intratumoral heterogeneity and immune microenvironment of two HPV-related cervical cancer types revealed by single-cell RNA sequencing","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204951","article-title":"Single-cell landscape highlights heterogenous microenvironment, novel immune reaction patterns, potential biomarkers and unique therapeutic strategies of cervical squamous carcinoma, HPV-associated and non-HPVA adenocarcinoma","volume":"10","author":"Qiu","year":"2023","journal-title":"Adv Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1186\/s12967-024-06011-y","article-title":"Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma","volume":"22","author":"Zhou","year":"2024","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41698-025-00948-z","article-title":"Deciphering the cellular and molecular landscape of cervical cancer progression through single-cell and spatial transcriptomics","volume":"9","author":"Xia","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-025-03432-5","article-title":"Deciphering the tumor immune microenvironment: single-cell and spatial transcriptomic insights into cervical cancer fibroblasts","volume":"44","author":"Lin","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223627","article-title":"T cell exhaustion in the cervical cancer tumor microenvironment: PD-1 overexpression and co-expression with TIGIT, Tim-3, LAG-3, and NKG2A","volume":"17","author":"Garc\u00eda-Barrientos","year":"2025","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8+ T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12672-025-01943-3","article-title":"Dynamic changes in peripheral blood immunophenotyping and its prognostic value in cervical cancer patients undergoing immune checkpoint blockade therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Discov Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1186\/s12885-025-15173-x","article-title":"Peripheral lymphocyte count as a prognostic marker in cervical cancer patients treated with immune checkpoint inhibitors: a retrospective study","volume":"25","author":"Dofutsu","year":"2025","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2664301","article-title":"Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer","volume":"22","author":"Bai","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179414","article-title":"Peripheral blood-based biomarkers for immune checkpoint inhibitors","volume":"22","author":"An","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00262-022-03221-5","article-title":"Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors","volume":"72","author":"Wei","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1038\/s41598-025-02597-5","article-title":"The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irAE onset, and prognosis","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0467","article-title":"Spatiotemporal immune determinants of response to immune rechallenge in advanced cervical cancer","volume":"16","author":"Lan","year":"2026","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106359","article-title":"Integrative multi-omics approaches to explore immune cell functions: challenges and opportunities","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-023-10246-2","article-title":"Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics","volume":"41","author":"Liu","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063563","article-title":"Immunotherapy and cancer: the multi-omics perspective","volume":"25","author":"Donisi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114392","article-title":"Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy","volume":"43","author":"Quek","year":"2024","journal-title":"Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat Genet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41698-024-00765-w","article-title":"Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images","volume":"8","author":"Patkar","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac959","article-title":"TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment","volume":"51","author":"Han","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/s41467-023-38333-8","article-title":"MetaTiME integrates single-cell gene expression to characterize the meta-components of the tumor immune microenvironment","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1063711","article-title":"Tertiary lymphoid structures are critical for cancer prognosis and immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.medj.2024.10.023","article-title":"Tertiary lymphoid structures and cancer immunotherapy: from bench to bedside","volume":"6","author":"Peyraud","year":"2025","journal-title":"Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00262-024-03856-6","article-title":"Targeting immune checkpoints on myeloid cells: current status and future directions","volume":"74","author":"Ma","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623436","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101550","article-title":"Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence","volume":"5","author":"Dai","year":"2024","journal-title":"Cell Rep Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1315","article-title":"Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancer","volume":"16","author":"Xu","year":"2026","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front","volume":"182","author":"Sch\u00fcrch","year":"2020","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"},{"key":"B58","doi-asserted-by":"publisher","first-page":"16994","DOI":"10.1038\/s41598-023-43435-w","article-title":"Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics","volume":"13","author":"Rivest","year":"2023","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:59Z","timestamp":1788869279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2026.1925452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1925452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1925452"}}